MedTrace Logo

Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)

NCT04318015 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 289

Last updated 2022-02-01

No results posted yet for this study

Summary

Triple blinded, phase III randomized controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients.

Conditions

  • COVID-19
  • Severe Acute Respiratory Syndrome

Interventions

DRUG

Hydroxychloroquine

All treatment will be administered orally.

DRUG

Placebo oral tablet

All placebo will be administered orally

Sponsors & Collaborators

  • National Institute of Respiratory Diseases, Mexico

    lead OTHER_GOV

Principal Investigators

  • Jorge Rojas-Serrano, MD, PhD. · National Institute of Respiratory Diseases - México

  • Rogelio Perez-Padilla, MD · National Institute of Respiratory Diseases - México

  • Felipe Jurado-Camacho, MD. MSc · National Institute of Respiratory Diseases - México

  • Ireri Thirion-Romero, MD, MSc · National Institute of Respiratory Diseases - México

  • Sebastian Rodríguez-Llamazares, MD, MPH · National Institute of Respiratory Diseases - México

  • Carmen Hernandez Cárdenas, MD, MSc · National Institute of Respiratory Diseases - México

  • Cristobal Guadarrama-Pérez, MD · National Institute of Respiratory Diseases - México

  • Alejandra Ramírez-Venegas, MD, MSc · National Institute of Respiratory Diseases - México

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2020-12-31
Completion
2021-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318015 on ClinicalTrials.gov